GP Oxan - Brand Version Steroid Oxandrolone

GP Oxan is the trademark name of the anabolic steroid Oxandrolone. Introduced in the US in 1964, Anavar is considered a Class I steroid. It is taken orally and has few known side Oxandrolone effects, binding well with the androgen receptor when taken in sufficient dosage.

Compared to other anabolic steroids available in the market GP Oxan is mildly anabolic, only slightly androgenic, and is not very toxic. It is also mild on the body's Hypothalamic-Testicular-Pituitary-Axis (HPTA) and does not aromatize or convert to estrogen a major problem for stronger anabolic steroids, which causes unwanted breast tissue to form (man boobs), called gynecomastia. As with any anabolic steroid however, high dosage of Anavar can reduce the production of luteinizing hormone (LH), halting the stimulation of Leydig cells in testicles to produce testosterone, and therefore can cause the testes to shrink or to atrophy. High dosages of Anavar (about 40-50mg) require Post Cycle Therapy (PCT) to stabilize protein catabolism and normalize the body's testosterone secretion. Anavar is also very popular because of its fat burning capability. Called a "fat-burning steroid," GP Oxan (Anavar) is said to reduce abdominal and visceral fat for those with the low to normal natural testosterone range.

Doctors usually prescribe Anavar for halting wasting related to AIDS and recovering involuntary weight loss to promote the regrowth of muscles. The drug Oxandrolone has also been used in treating cases of Osteoporosis in the past, showing partially successful results. Due to bad publicity in the abuse of the steroid however, Searle Laboratories (now Pfizer, Inc.) discontinued the sale of oxandrolone, but was later picked up by Bio-Technology General Corporation (now Savient Pharmaceuticals, Inc.), released in 1995 under the trademark name Oxandrin. The Food and Drug Administration (FDA) approved Oxandrolone for orphan drug status in treating weight loss caused by HIV, Turner's syndrome, and alcoholic hepatitis. Oxandrolone has also showed positive results in treating hereditary angioedema and anemia. In a study of the effect of Oxandrolone on burnt victims, those treated with Oxandrolone were found to have improved body composition, reduce hospital stay time, and preserved muscle mass.

Because GP Oxan is a mild steroid, it may require a higher dosage compared to stronger steroids. It is not without side effects however. Those thinking of upping their dosage for this drug just because it is comparably mild should think twice. Some studies show that there is a link between the prolonged use of Anavar and liver toxicity, similar to the effects of 17-alkylated steroids. Even in lesser dosages, some users have reported side effects such as nausea, bloating, itching (hives), gastro-intestinal problems, depression, skin rash, diarrhea, yellowing of the skin or eyes, unusual bleeding, swelling, and unusually colored stools. In rare cases, serious or even fatal liver problems can occur, as well as the development of heart disease. Regular laboratory testing is highly recommended when taking this drug, to closely monitor the liver and to ensure that low density lipoprotein (LDL; also called the 'bad cholesterol') has not increased.
For bodybuilders, normal dose for a first time Anavar user is considered to be at 10-30 mg's per day. However, 10 mg may be sufficient for someone who has never taken anabolic steroids beforehand. Higher dosages may lead to androgen receptor damage, HPTA suppression, and liver damage.

Bodybuilding And Creatine

Creatine (methylguanidine-acetic acid) was discovered in 1832 by Michel Eugene Cheverul. Later on, in 1834 Justus von Lieburg “confirmed” that creatine was a normal part of meat. It was also found that there was more creatine in wild animals which underwent more exercise than animals that were living in captivity which exercised less.
During the early part of the 1900s by using creatine as a supplement allowed for a boost in creatine in animals. Later on, phosphocreatine (creatine phosphate or phosphorylated creatine) was discovered in the year of 1927. Then in 1934, the creatine kinase (the enzyme that “catalyzes” phosphocreatine was found). Finally, in 1968, phosphocreatine was found in the process of recuperating from exercise.
In foods, creatine is found primarily in red meat and fish. Eaten creatine is then eventually sent to the bloodstream. Creatine is also synthesized within the body by the liver, kidney and pancreas, although this primarily takes place in the liver. This is done in two steps: the first step is when an amidine group from arginine goes to glycine to make guanidinoacetic acid. Then in step two, a methyl group goes to a guanidinoacetic acid from S-adenoslymthionine forming creatine. In the synthesis of creatine, there are some controls on it so that when there is less creatine in one’s diet, there will be more synthesis of creatine in the body. In opposition, if there is a lot of creatine present in one’s diet, then there will be less creatine synthesis in the body.
The storage of creatine in the body occurs in two forms; in the form of phosphocreatine or simply creatine. In the average adult male weighing 70kg, there is 120g of creatine of which 95% is found in the skeletal muscle. Some of the creatine goes to other various parts of the body such as the heart and brain. Of all the creatine in the skeletal muscles, 60-70% of that creatine is phosphocreatine. And because it is phosphocreatine, it cannot leave the membranes.